Colonic stenting was introduced for palliation of malignant large-bowel obstruction (MLBO) more than 20 years ago but remains controversial.
C olorectal cancer is the third most common malignant tumor and the third most common cause of cancer death in the United States. 1 An estimated 8% to 29% of patients with colorectal cancer present with acute malignant large-bowel obstruction (MLBO) and require emergency management. 2 Furthermore, an estimated one-third of patients presenting with acute MLBO will not undergo curative resection. 3 Traditionally, management of acute large-bowel obstruction involved an open diversion or resection, with perioperative morbidity as high as 46% and mortality as high as 28% for each procedure. [4] [5] [6] [7] Beginning in the early 1990s, physicians started experimenting with self-expanding metal stents to manage colonic obstructions. 8 In the past decade, a number of studies 3, [9] [10] [11] [12] [13] [14] [15] [16] have evaluated the use of self-expanding metal stents for palliation of malignant obstruction. Although initially there was strong support for palliative colonic stenting, its safety has been questioned based on 2 randomized clinical trials that closed early because of an unexpectedly high perforation rate. 17, 18 However, a recent highly publicized small trial reported encouraging early results, 19 supporting the belief that experienced endoscopic physicians might have good results. Most of the studies evaluating outcomes of palliative colonic stenting that follow up patients beyond 30 days are small (<50 patients), 1 0,1 1 ,1 7, 2 0 -2 3 conducted at single centers, 9 -1 1 , 2 0 -2 2 and located in academic or referral centers. 11, 17, 18 Furthermore, although many of these small studies had heterogeneous populations, they did not undertake robust matching that would allow for adequate comparison. 17, 18, 20, 22 Our objective was to compare the 90-day and 1-year outcomes of patients who presented to the emergency department (ED) with MLBO and subsequently underwent palliative stenting vs stoma using a large, realworld, multicenter database.
Methods
We because that was when colonic stenting first had its own ICD-9-CM procedure code. To verify that patients were treated initially with stent or stoma with palliative intent, patients who underwent resection within 1 year of the index procedure were excluded from analysis ( Figure) . We further excluded patients who resided outside New York State at the time of initial treatment.
Key Points
Question What is the comparative effectiveness of palliative stenting vs stoma creation in patients with colorectal cancer and malignant large-bowel obstruction when resection is not planned?
Findings This statewide cohort study of 345 patients found no differences in postprocedure complication rates among patients with palliative stenting and those with stoma. However, palliative stenting was associated with lower occurrence of prolonged length of stay and discharge to a rehabilitation or nursing facility, and hospital charges were also lower after stenting.
Meaning
In patients with malignant large-bowel obstruction, palliative stenting is safe and improves the efficiency of care with obvious quality-of-life benefits when compared with stoma creation. Patient characteristics included age, sex, race and ethnicity (white, black, Hispanic, or other), insurance status (Medicare, Medicaid, commercial, or other), tumor location (colon, sigmoid, or rectum), comorbidities, and hospital volume and geographic location. Hospital volume of MLBO procedures was reported as tertiles with the following cutoffs per year: low volume, 0 to 4 procedures; medium volume, more than 4 but 8 procedures or less; and high volume, more than 8 procedures. During our analysis of outcomes, hospital volume was treated as a continuous variable. Hospital location (urban or rural) was determined by the population of the county where the hospital was located using the definition from the Office of Management and Budget (urban was defined as a population of ≥10 000). Relevant comorbidities were identified using algorithms validated by Elixhauser et al. 24 Distance to the closest high-volume institution (defined by number of MLBO procedures as above) was determined by zip codes of residence and facilities. Our main outcomes of the study were subsequent operation and readmission within 90-day and 1-year follow-up. Our secondary outcomes were in-hospital death, major events (including acute myocardial infarction, stroke, pulmonary embolism, and shock), surgical complications (including iatrogenic or bleeding complications), perforation (defined as ICD-9-CM diagnosis code of peritonitis 567.21, 567.22, 567.29, or 567.9 after stent placement), transfusions, total parenteral nutrition, length of stay (LOS), hospital charges, and other than routine discharge status (including discharge to skilled nursing facility, short-term rehabilitation facility, or home health care service). Procedures included in subsequent operation were colostomy formation (ICD-9-CM codes 46.10, 46.11, and 46. Baseline characteristics were compared, and events and percentages were presented. The χ 2 tests for categorical variables were used to compare differences in baseline characteristics and outcome events. The t test was used to compare age between groups. Wilcoxon rank sum tests were used to compare distance to closest high-volume facilities, differences in LOS, and total charges. Multivariable analyses with a generalized linear mixed model and propensity score matching were used to compare outcomes between groups, using stenting alone as the reference group. The generalized linear mixed model accounted for hospital clustering and adjusted for patient demographics, year of surgery, comorbidities, and hospital volume and location. Propensity scores for each patient were obtained from a multivariable logistics regression model based on patient characteristics, year of surgery, comorbidities, and hospital volume and location. Nearest neighbor matching was performed at a 1:1 fixed ratio, using a caliper width of 0.2 of the SD of the logit of the propensity score. Balance in patient and facility characteristics was examined. Differences in outcomes between the 2 groups were assessed with stratified χ 2 tests in the matched cohort. All analyses were performed using SAS statistical software, version 9.3 (SAS Institute Inc). Significance level was 2-sided and set at P < .05.
Results
There Table 2) . This group of patients was also less likely to receive total parenteral nutrition after stenting (16 [9.3%] vs 37 [17.9%], P = .02) and had a shorter LOS (median, 10 vs 13 days; P < .001). No difference was found in readmission within 90-day and 1-year follow-up between the groups. However, subsequent operation at 1-year follow-up was more common among patients who underwent stenting than those undergoing stoma creation (23 [13. 4%] vs <11 [<6.4%], P = .004). Most patients undergoing subsequent operation within 1 year after initial stenting received another stenting procedure (>70%). The number of perforations was so low (<10 events) that it cannot be reported according to data use agreement.
In adjusted analysis, patients undergoing stenting were significantly less likely to experience prolonged LOS (odds ratio [OR], 0.50; 95% CI, 0.26-0.97; P = .04) and other than routine discharge (OR, 0.14; 95% CI, 0.07-0.28; P < .001) when compared with stoma creation (Table 3) . Patients undergoing stenting also had lower risk of inpatient death (OR, 0.40; 95% CI, 0.14-1.10; P = .08), had lower risk of receiving a transfusion (OR, 0.57; 95% CI, 0.31-1.06; P = .07) or total parenteral nutrition (OR, 0.44; 95% CI, 0.19-1.00; P = .05), and were less likely to incur high hospital charges (OR, 0.56; 95% CI, 0.29-1.11; P = .09). No significant difference was found in readmission at 90 days and 1 year or subsequent operation at 90 days between groups. Patients undergoing stenting were more likely to undergo subsequent operation within 1 year than those undergoing stoma
Discussion
This is the first large study, to our knowledge, to compare shortterm (index admission) and long-term (90 days and 1 year) outcomes of patients with MLBO treated with palliative stent or stoma creation. Overall, most stenting was performed in patients who live near high-volume centers and by physicians in high-volume centers. We found that during the index admission, patients who underwent palliative stenting had lower rates of in-hospital death, discharge to rehabilitation or nursing facilities (vs home), prolonged LOS, and high hospital charges. Our findings indicate that for patients who are not deemed to be candidates for resection, stenting appears to offer significant benefits compared with stoma creation. Strengths of our study include its longitudinal analysis, propensity score matching, and relatively large sample size compared with the existing literature.
The goals of palliation are distinctly different from curative resection and include avoidance of complications or stoma creation, shorter LOS, fewer health care transitions, and appropriate admissions to hospice. 25 Therefore, beyond clear benefits of palliative stenting, such as reduced likelihood of inhospital death, other benefits, such as reduced likelihood of 
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prolonged LOS or discharge to a nursing facility, are of particular importance in palliative management of MLBO. In addition, there is a substantial advantage in avoiding the quality-of-life compromise that happens with a colostomy creation. Although there was a need for more subsequent operations in patients undergoing palliative stenting at 1 year, most of these subsequent operations were for restenting and therefore still less invasive than exploratory laparotomy or stoma creation.
Other studies with more than 30-day follow-up have mostly been small single-center 10, 11, [20] [21] [22] 26 or academic or referral center cohorts, 11, 17, 18 limiting their generalizability. For example, Tomiki et al 21 followed up a small sample (n = 17) beyond 30 days, with a mean survival period of 134 days. They found that the mean duration to readmission (129 vs 188 days) was shorter in the stent group compared with patients who underwent colostomy but was likely underpowered to determine statistical significance. Another important finding of our study is that palliative stenting is safe, with a procedural complication rate and perforation rate less than 6% and fewer complications compared with stoma on adjusted analysis. This complication rate is lower than other smaller studies 21, 23 (42%-76%), and the perforation rate is lower than several European studies 17,18 (10%-13%). The lower rates observed in our study may reflect use by more experienced endoscopists, a larger sample size, and perhaps progression on the learning curve. Finally, we found that patients who lived closer to highvolume hospitals were more likely to undergo stenting. Because this is often an urgent or emergency admission to the hospital, patients may not have the chance to drive long distances to centers that offer this specialized procedure. Therefore, because regionalization is not as feasible as it may be for rectal resection, 27 more physicians should be trained to perform stenting.
Limitations
Our study has several limitations. Ideally, it would be desirable to learn about the use of adjuvant chemotherapy before presentation to the ED. However, it is less likely that patients already undergoing chemoradiation treatment would present to the ED with MLBO; furthermore, it is hard to imagine differential use of chemoradiation treatment in patients who ultimately undergo stenting vs stoma. We also do not have 
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Long-term Outcomes of Emergency Stenting vs Stoma in Malignant Large-Bowel Obstruction information about tumor size or distance from anal verge, but our findings apply strictly to patients who do not undergo resection within 1 year of presenting to the ED with MLBO. This likely limits the biases associated with patients being better candidates for stenting and bridge to surgery. In terms of applicability, clinicians do not always know with certainty whether patients with MLBO presenting to the ED will be candidates for resection within 1 year of presentation. Still, our evidence offers clinicians further resources to guide the decision-making process when faced with the uncertainty of the individual patient's clinical course. Finally, approximately 60% of patients who underwent stenting were treated at high-volume centers, meaning that our results are heavily weighted toward more experienced endoscopists. Generalization of our results to centers without experienced endoscopists should therefore be done prudently.
Conclusions
In patients with MLBO who are not likely resection candidates, stenting is safe and improves the efficiency of care with obvious quality-of-life benefits. In experienced centers, where most stenting is performed, perforation rates are low and outcomes successful. Patients should be counseled on the increased risk of restenting. Author Contributions: Dr Sedrakyan had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. 
